PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy Posted on January 26, 2026January 28, 2026 by edgover
PulseSight Completes Enrollment in Gene Therapy Trial Posted on January 22, 2026January 23, 2026 by edgover
A New Attack on Blindness: PulseSight Completes Key Safety Trial for Novel Dry AMD Gene Therapy Posted on January 22, 2026January 23, 2026 by edgover
Research supports that iron dysregulation may drive AMD Posted on October 28, 2025January 15, 2026 by edgover
PulseSight Therapeutics Builds Non-Viral Gene Therapy Pipeline For AMD Posted on September 15, 2025January 15, 2026 by fowlerat
Study Connects Iron Regulation and Vision Loss Posted on September 4, 2025January 15, 2026 by edgover
PulseSight to highlight new data on the role of iron and transferrin in AMD at EURETINA 2025 Posted on September 4, 2025January 15, 2026 by edgover
PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025 Posted on September 4, 2025January 15, 2026 by edgover
A new treatment for dry AMD and tackling peanut allergies Posted on August 15, 2025January 15, 2026 by fowlerat
